Altogether, it is possible that higher capacity to phosphorylate STAT1 in response to IFN-γ can be a marker able to distinguish the RA patients who are amenable to treatment with TNF or IL-6 blockers. The gene discussed is IFNG; the disease is rheumatoid arthritis.